Skip to content

Inventories at other companies

Merck & Co. logo
Merck & Co.MRK
$6.2B+36.0%
Delcath Systems logo
Delcath SystemsDCTH
$9.81M+37.5%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$58.38M-10.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$18.86M+123%
Gilead Sciences logo
Gilead SciencesGILD
$2.42B+20.1%
United Therapeutics logo
United TherapeuticsUTHR
$178.3M+7.8%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s inventories?
Citius Oncology, Inc. (CTOR) reported inventories of $22.66M in Q1 2026.
How has Citius Oncology, Inc.'s inventories changed year-over-year?
Citius Oncology, Inc.'s inventories increased by 47.7% year-over-year, from $15.34M to $22.66M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.